Sei Investments Co. Has $3.01 Million Holdings in Brainsway Ltd. Sponsored ADR $BWAY

Sei Investments Co. increased its stake in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 262.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 226,378 shares of the company’s stock after buying an additional 163,925 shares during the quarter. Sei Investments Co.’s holdings in Brainsway were worth $3,009,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Y.D. More Investments Ltd grew its position in Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after acquiring an additional 157,042 shares during the period. ARK Investment Management LLC bought a new position in shares of Brainsway during the fourth quarter valued at $2,422,000. UBS Group AG lifted its holdings in shares of Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after acquiring an additional 60,877 shares during the period. Sigma Planning Corp boosted its stake in shares of Brainsway by 369.1% in the 1st quarter. Sigma Planning Corp now owns 70,363 shares of the company’s stock valued at $935,000 after purchasing an additional 55,363 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Brainsway in the 1st quarter valued at $433,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BWAY. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. BTIG Research began coverage on shares of Brainsway in a research report on Monday, July 20th. They issued a “buy” rating and a $18.00 price target on the stock. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Brainsway in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $15.67.

Brainsway Stock Performance

Shares of BWAY opened at $15.50 on Friday. The firm has a market capitalization of $622.01 million, a price-to-earnings ratio of 44.29 and a beta of 1.24. The business’s fifty day moving average price is $15.03 and its two-hundred day moving average price is $14.22. Brainsway Ltd. Sponsored ADR has a 52 week low of $5.84 and a 52 week high of $17.35.

Brainsway (NASDAQ:BWAY) last released its earnings results on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.05 by $0.07. The company had revenue of $15.53 million during the quarter, compared to analysts’ expectations of $14.63 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. As a group, research analysts forecast that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current year.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.